Athos, an autoimmune and cancer biotech, is raising $35M for clinical trials

16 Feb 2024

Phase 1PROTACsPhase 2

Athos Therapeutics is raising a $35 million Series B, it confirmed to Endpoints News . The Torrance, CA-based biotech will deploy the money on its AI-based precision small molecules for autoimmune diseases and various cancer indications. About $10 million of the expected haul will go toward the lead asset, an inflammation and mucosal healing-targeted treatment for inflammatory bowel disease, CEO Dimitrios Iliopoulos said in an emailed statement. The biotech anticipates Phase I topline data by March and plans to start a Phase IIa by the third quarter of 2024, he added, noting the capital will also fund it through that study.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

MAD Apparel, Inc.

Athos Therapeutics, Inc.

Indications

NeoplasmsAutoimmune DiseasesInflammation

[+1]

Targets

Drugs

Chat with Hiro

Hot reports

GPRC5D Target Patent Research Report

Patsnap Synapse

Global Drug R&D Express (July 2024)

PatSnap Synapse

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Patsnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.